Volume 30, Number 10—October 2024
Dispatch
Oxacillinase-484–Producing Enterobacterales, France, 2018–2023
Cécile Emeraud, Sandrine Bernabeu, Delphine Girlich, Inès Rezzoug, Agnès B. Jousset, Aurélien Birer, Thierry Naas, Rémy A. Bonnin, and Laurent Dortet
Table
Antimicrobial susceptibility of OXA-484-producing isolates received at the French National Reference Center for Carbapenem-resistant Enterobacterales, 2018–2023*
| Species and carbapenemase type | MICs for antimicrobial drugs |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ERT | IMI | IMI/ REL | MEM | MEM/VAB | CPM | CTZ | CTZ/ AVI | CFT/ TAZ | AZT | AZT/ AVI | TMC | COL | |
| Escherichia coli OXA-484 | |||||||||||||
| None, n = 26 | |||||||||||||
| MIC | ≤0.25–8 | ≤0.25–1 | ≤0.25–1 | ≤0.25–2 | ≤0.25–2 | ≤1–2 | ≤0.25–8 | ≤0.25–1 | 0.5–>8 | ≤0.25–2 | ≤0.25–2 | 32–>128 | 0.25–1 |
| MIC50 | 0.5 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤1 | ≤0.25 | ≤0.25 | 2 | ≤0.25 | ≤0.25 | 64 | 0.5 |
| MIC90 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | ≤1 | 2 | 0.5 | >8 | 1 | 1 | >128 | 1 |
| ESBL, n = 5 | |||||||||||||
| MIC | ≤0.25–1 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | 2–>16 | 1–>16 | ≤0.25–0.5 | 1–>8 | 2–>16 | ≤0.25–1 | 32–128 | 0.25–0.5 |
| MIC50 | 0.5 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | 16 | 4 | 0.5 | 8 | >16 | ≤0.25 | 32 | 0.25 |
| MIC90 | 1 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | >16 | >16 | 0.5 | >8 | >16 | 1 | 128 | 0.5 |
| Acquired, n = 26 | |||||||||||||
| MIC | 0.5–4 | ≤0.25–2 | ≤0.25–1 | ≤0.25–2 | ≤0.25–1 | ≤1–16 | 4–>16 | ≤0.25–4 | 1–>8 | 1–>16 | ≤0.25–8 | 32–>128 | 0.5 |
| MIC50 | 1 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | 8 | >16 | 2 | >8 | >16 | 2 | >128 | 0.5 |
| MIC90 |
4 |
0.5 |
0.5 |
0.5 |
0.5 |
4 |
>16 |
4 |
>8 |
>16 |
4 |
>128 |
0.5 |
| E. coli OXA-484 + NDM | |||||||||||||
| ESBL, n = 2, | >16 | 8–>8 | 8–>8 | >16 | >16 | >16 | >16 | >16 | >8 | >16 | 1–2 | >128 | 0.5 |
| Acquired, n = 2, |
2–4 |
>8 |
>8 |
>16 |
>16 |
>16 |
>16 |
>16 |
>8 |
>16 |
4–2 |
>128 |
0.5 |
| E. coli OXA-484 + OXA-48, acquired, n = 1 |
0.5 |
2 |
1 |
4 |
2 |
8 |
1 |
0.5 |
>8 |
4 |
2 |
32 |
0.5 |
| Citrobacter youngae OXA-484, acquired, n = 1 |
2 |
0.5 |
0.5 |
0.5 |
0.5 |
1 |
4 |
≤0.25 |
>8 |
1 |
≤0.25 |
>128 |
0.5 |
| Klebsiella pneumoniae OXA-484, n = 1 |
1 |
≤0.25 |
≤0.25 |
0.5 |
≤0.25 |
≤1 |
≤0.25 |
≤0.25 |
1 |
≤0.25 |
≤0.25 |
128 |
0.5 |
| Total, n = 64 | |||||||||||||
| MIC50 | 2 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | 4 | 8 | 0.5 | >8 | 16 | 1 | 128 | 0.5 |
| MIC90 |
4 |
1 |
1 |
2 |
1 |
>16 |
>16 |
2 |
>8 |
>16 |
4 |
>128 |
0.5 |
| % Susceptible† | 31.3 | 95.3 | 93.8 | 92.2 | 93.8 | 42.2 | 39.1 | 93.8 | 34.4 | 35.9 | 54.7 | 0 | 100 |
*AVI, avibactam; AZT, aztreonam; CFT, ceftolozane; COL, colistin; CPM, cefepime; CTZ, ceftazidime; ESBL, extended-spectrum β-lactamase; IMI, imipenem; ERT, ertapenem; MEM, meropenemNDM, New Delhi metallo-β-lactamase; ; OXA, oxacillinase; REL, relebactam; TAZ, tazobactam; TMC, temocillin; VAB, vaborbactam. †Interpreted according to EUCAST guidelines.
Page created: August 14, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.